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The development of IBS symptoms – altered bowel function and abdominal cramping in a
subset of adult subjects exposed to severe enteric infections opened up an unprecedented
opportunity to understand the etiology of this poorly understood disorder. Perhaps, for the
reasons that these symptoms follow a severe enteric infection, andmucosal biopsy tissues
are readily available, the focus ofmost studies thus far has been to show thatmild/low-grade
mucosal inﬂammation persisting after the initial infection has subsided causes the IBS
symptoms. Parallel studies in non-infectious IBS patients, who did not have prior enteritis,
showed similar mild mucosal inﬂammation.Together, these studies examined the mucosal
inﬁltration of speciﬁc immune cells, increase of select inﬂammatory mediators, mast cell
and enterochromafﬁn cell hyperplasia, and epithelial permeability. In spite of the fact that
the data on these topics were not consistent among different studies and clinical trials
with prednisone, ﬂuoxetine, and ketotifen failed to provide relief of IBS symptoms, the
predominant conclusions were that mild mucosal inﬂammation is the cause of IBS symp-
toms. However, the circular smooth muscle cells, and myenteric neurons are the primary
regulators of gut motility function, while primary afferent neurons and CNS play essential
roles in induction of visceral hypersensitivity – no explanation was provided as to how mild
mucosal inﬂammation causes dysfunction in cells far removed. Accumulating evidence
shows that mild mucosal inﬂammation in IBS patients is in physiological range. It has little
deleterious effects on cells within its own environment and therefore it is unlikely to affect
cells in the muscularis externa. This review discusses the disconnect between the focus
on mild/low-grade mucosal inﬂammation and the potential mechanisms and molecular dys-
functions in smooth muscle cells, myenteric neurons, and primary afferent neurons that
may underlie IBS symptoms.
Keywords: functional bowel disorders, visceral pain, inflammatory bowel disease, enteric neurons, smoothmuscle,
immune cells, epithelial permeability, gut inflammation
IBS is a complex disorder – its origins are unknown and the
conventional diagnostic approaches are unable to identify an
organic cause. The absence of an identiﬁable abnormality frus-
trates physicians – they cannot respond satisfactorily to provide
relief of symptoms; it frustrates patients – they see no end to mor-
bidity the disorder carries; it frustrates pharmaceutical compa-
nies – their attempts to develop therapeutic agents have repeatedly
fallen short; it frustrates scientists – they are unable to pinpoint the
cellular and system wide mechanisms of organ dysfunction. Is it
possible that an open-minded look at post-infectious IBS (PI-IBS)
will give a new sense of direction that would move us forward in
managing a disorder that causes signiﬁcant morbidity and carries
huge socio-economic burden?
Chaudhary and Truelove (1962) ﬁrst reported that about a
quarter of IBS patients in their study had an episode of severe
diarrhea in recent past. This unusual observation did not receive
immediate attention it deserved. A publication, almost 32 years
later, sparked wider interest in the development of IBS symp-
toms in about a quarter of subjects exposed to enteric infec-
tions in a community setting (McKendrick and Read, 1994). This
study noted that the severity of acute illness during enteritis is
greater in patients, who developed PI-IBS+ than in those who
did not PI-IBS−. Other publications in the following years con-
ﬁrmed these ﬁndings (Gwee et al., 1996; Neal et al., 1997; Spiller
et al., 2000; Spiller, 2003, 2007; Mearin et al., 2005). Later stud-
ies in larger cohorts of patients found that the probability of
developing PI-IBS is small if diarrhea lasts less than a week –
thereafter it increases proportionally with the duration of symp-
toms during enteric infection, speciﬁcally diarrhea (Neal et al.,
1997; Wang et al., 2004). The PI-IBS patients present with the
symptoms of altered bowel function – diarrhea (∼63%), consti-
pation (∼24%), and alternating diarrhea/constipation (∼13%),
intermittent abdominal cramping and urgency (Dunlop et al.,
2003a).
The above ﬁndings present an unprecedented opportunity
to understand the etiology of at least one type of IBS – PI-
IBS – and possibly open up the window to understand it in
all types of IBS. In this regard, McKendrick and Read (1994)
speculated that several risk factors – “increase in epithelial per-
meability, elevation of neuropeptides, stimulation of primary
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afferent nerves by inﬂammatory mediators, axonal reﬂexes gen-
erated by degranulating mast cells, and contractions of vascular
and intestinal smooth muscle”might contribute to the symptoms
of PI-IBS. Taking cues from these speculations, several clinical
studies have investigated these and other potential mechanisms
that might contribute to the symptoms of motility dysfunc-
tion, intermittent abdominal cramping, and urgency in PI-IBS
patients. The goal of this review is to discuss these ﬁndings in
light of our current clinical and basic science understandings of
regulation of gut colonic motility function, visceral hypersen-
sitivity (VHS), immune responses, and epithelial barrier func-
tion. The focus is on understanding the roles of smooth muscle
cells, enteric neurons, and primary afferent neurons in causing
motility dysfunction and VHS to colorectal mechanical events –
rapid and large amplitude compression by colonic contractions or
distension.
ALTERED MOTILITY FUNCTION AND PERSISTENT MUCOSAL
INFLAMMATION IN PI-IBS
MOTOR CORRELATES OF DIARRHEA/CONSTIPATION AND URGENCY
Most publications treatmotility dysfunction in IBS as a black box –
this might limit our ability to understand the underlying mech-
anisms that cause it. This section brieﬂy introduces the motor
correlates of the symptoms of IBS – diarrhea, constipation, and
urgency (Sarna, 2010). The enteric neurons and circular smooth
muscle cells are the core regulators of motility function. The
inputs from the central nervous system, spinal cord, inﬂammatory
mediators, stress mediators, and hormones modulate the function
of these two cell types to inﬂuence motility function/dysfunction.
Therefore, one must look for the innate cellular mechanisms of
motility dysfunction in these two cell types and which of the above
factors modulate them.
The colon generates three distinct types of contractions – giant
migrating contractions (GMCs), rhythmic phasic contractions
(RPCs), and tone (Sarna, 2010). Each type of contraction has a
distinctmotor function. Two critical requirements for gut contrac-
tions to propel luminal contents are that they occlude the lumen
partially or completely and propagate in the anal direction (Sarna,
2010). The extent of luminal occlusion relates to the amplitude
of the contraction. The GMCs are large amplitude contractions
that strongly occlude the limen and propagate over long distances
in the colon – thus producing mass movements. The strong com-
pression of a colon segment by a GMC also initiates descending
inhibition that facilitates rapid propulsion by accommodating the
large bolus being propelled (Sarna, 2007). When GMCs occur in
the distal colon, the descending inhibition relaxes the internal
anal sphincter to allow passage of feces during defecation. The
mass movement by a GMC provides the propulsive force for rapid
expulsion of feces (Bampton et al., 2000; Figure 1). The rapid
and forceful propulsion against closed anal sphincters distends the
intervening segment to induce the sensation of urgency. By con-
trast, the RPCs in the colon are much smaller in amplitude and
they do not propagate or propagate over short distances – causing
mainlymixing and turning over of luminal contents (Sarna, 2010).
Increase in tone by itself does not cause propulsion or mixing and
turning over of luminal contents – however, it potentiates these
functions of RPCs. In health, the GMCs occur only a few times
a day.
Accumulating evidence from studies of colonic motility in
healthy subjects and in patients with diarrhea-predominant IBS
FIGURE 1 | Spontaneous GMCs in the colon associated with urges to
defecate and defecation.The ﬁrst three GMCs (shown by upward arrows)
started near the splenic ﬂexure and terminated in the sigmoid colon. The
second and third GMCs caused urges to defecate. The fourth GMC
propagated to the end of the colon and caused defecation. (Reproduced with
permission from Bampton et al., 2000.)
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(IBS-D), constipation-predominant IBS (IBS-C), and alternating
constipation/diarrhea-predominant IBS (IBS-C/D) and in experi-
mental models shows that diarrhea in IBS-D patients results from
a signiﬁcant increase in the frequency of GMCs and constipation
occurs due to a decrease in their frequency (Bassotti et al., 1988,
2003; Chey et al., 2001; Rao et al., 2004). The RPCs play a minor
role in these motor dysfunctions. Therefore, the mechanisms that
regulate the stimulation and propagation of GMCs lie at the root
of motor dysfunction in IBS. Note that the smooth muscle cells
and myenteric neurons together regulate all three types of colonic
contractions (Sarna, 2010).
MUCOSAL INFLAMMATION IN PI-IBS
A few studies noted an increase in the numbers of select types
of immune cells and inﬂammatory mediators – T lymphocytes,
macrophages, IL-1β, and IL-2 mRNA in the epithelial cells and
lamina propria over those in healthy controls at various times after
the initial enteric infection (Gwee et al., 1999, 2003; Spiller et al.,
2000; Wang et al., 2004). Other studies noted similar increases in
these immune cells and inﬂammatory mediators in the mucosa of
IBS patients, who did not have a recent episode of enteritis (non-
infectious/non-inﬂammatory IBS, NI-IBS. (Chadwick et al., 2002;
Lee et al., 2008; Cremon et al., 2009). The suggestion was that this
mucosal inﬂammation might account for motility dysfunction in
IBS patients. All studies characterized the immune response in IBS
patients as mild/low-grade. However, the unanswered questions
are: (1) is this mild immune response sub-clinical or pathogenic?
(2) Does it extend to the muscularis externa to cause smooth
muscle and myenteric neuronal dysfunctions? The inﬂammatory
mediators have to be in direct contact with their effector cells to
impair their function.The biological effects of inﬂammation depend
on its intensity.
Inﬂammatory bowel disease (IBD; comprised of ulcerative coli-
tis and Crohn’s disease) and microscopic colitis (lymphocytic coli-
tis and collagenous colitis) are twomajor inﬂammatory conditions
in the colon. These and other inﬂammatory conditions show a
very clear gradient in the intensity of immune response (Cremon
et al., 2009; Figure 2). The inﬂammation in IBD is transmural
and most severe of all when the inﬁltration/activation of immune
cells and generation of oxidative/nitrosative stresses are considered
(Pravda, 2005; Shi et al., 2011). The increase of these inﬂamma-
tory mediators in the muscularis externa impairs smooth muscle
and myenteric neuronal functions in vivo and in vitro by their
presence in the microenvironments of these cells. The inten-
sity of inﬂammation in IBD is severely pathogenic – it disrupts
the mucosal layer and impairs the functions of almost all cell
types in the colon wall. During remission, the intensity of the
mucosal immune response decreases closer to that in microscopic
colitis (Figure 2). Endoscopic examination shows apparently nor-
mal macroscopic appearance in patients with microscopic colitis.
However, this level of inﬂammation compromises the epithelial
transport function, resulting in secretory diarrhea in microscopic
colitis (Protic et al., 2005). There is no evidence that the mildly
pathogenic mucosal inﬂammation in microscopic colitis spreads
to the muscularis externa to impair smooth muscle and enteric
neuronal functions.
The luminal pathogens continually challenge the epithelial bar-
rier in healthy subjects. However, the mucosal immune system
keeps small challenges from these pathogens in check by main-
taining a low-level immune response. This level of inﬂammation is
physiological – it does not affect integrity of the epithelial barrier,
epithelial transport function, and it prevents the inﬂammatory
response from spreading to the outer layers – submucosa and
muscularis externa. The intensity of mucosal immune activation
in IBS patients is signiﬁcantly less than that in lymphocytic colitis
patients, but the inﬁltrates in both types of patients are signiﬁ-
cantly greater than those in healthy controls subjects (Chadwick
et al., 2002; Cremon et al., 2009; Figure 2). However, the intraep-
ithelial lymphocytes (IELs) in IBS patients are well within the
normal range of less than 20 per 100 epithelial cells in healthy
FIGURE 2 | Relative counts of total immune cells in colonic
lamina propria of healthy controls (HC), and patients with
irritable bowel syndrome (IBS), microscopic colitis (MC),
ulcerative colitis in remission (rUC), and active ulcerative colitis
(aUC).The total cell counts increase almost linearly with the severity
of inﬂammation and its pathogenic effects. Up to a certain level, the
total cell counts are physiological/sub-clinical. Thereafter, the intensity
of pathogenic effects increases with increases in total immune cell
counts. (Reproduced with permission and modiﬁed from Cremon
et al., 2009.)
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subjects. There is no evidence that the intensity of immune
response in IBS patients signiﬁcantly impairs the epithelial trans-
port function. Therefore, even though there is a statistical increase
in the inﬁltration/activation of a few types of immune cells in IBS
patients, the intensity of mucosal inﬂammation remains within
the physiological/sub-clinical range (Figure 2). It is noteworthy
that only about 50% of IBS patients show a signiﬁcant inﬁltration
of immunocytes – they are undetectable in the remaining 50% of
the patients, even though they have the same symptoms as those
with mild mucosal inﬂammation (Cremon et al., 2009).
Other ﬁndings support the gradient in mucosal inﬂammation
in inﬂammatory diseases of the colon. Myeloperoxidase (MPO), a
marker of neutrophil activation,measured by mucosal patch tech-
nique, increases signiﬁcantly in active ulcerative colitis (300-fold),
inactive colitis (ﬁvefold), collagen colitis (ﬁvefold), celiac disease
(sixfold), and IBS (fourfold; Kristjansson et al., 2004). The cor-
responding fold-increases for eosinophil cationic protein (ECP),
a marker of eosinophil activation are 11 in ulcerative colitis, 1 in
inactive colitis, 2.5 in collagen colitis, 1 in celiac disease, and 1 in
IBS – only the 11-fold increase in ulcerative colitis patients is sig-
niﬁcant. The eosinophil granulocyte is a potent proinﬂammatory
cell that releases several highly toxic proteins, including ECP and
major basic protein (MBP; Venge and Peterson, 1989). The fecal
leukocyte markers in IBS patients are not different from those in
healthy controls – they are modestly elevated in collagenous colitis
and several-fold in IBDpatients (Silberer et al., 2005; Lettesjo et al.,
2006).
The PI-IBS or IBS patients do not have secretory diarrhea.
They have motor diarrhea – frequent unformed stools (Read,
1986). Motor diarrhea results from frequent mass movements
due to increase in the frequency of GMCs, which signiﬁcantly
decreases the duration of fecal contact with the mucosa. Of course,
a sub-clinical impairment of epithelial function might contribute
marginally to unformed stools. Smooth muscle cells and myen-
teric neurons are the ﬁnal regulators of GMCs as well as the
other two types of gut contractions – RPCs and tone. Only the
inﬂammatory mediators, stress mediators, hormones, and neuro-
transmitters that directly make contacts with the smooth mus-
cle cells/myenteric neurons can alter their function. There is no
evidence that a sub-clinical mucosal immune activation in IBS
patients spreads to the muscularis externa. One report of low-
grade inﬁltration of lymphocytes in the jejunal myenteric plexi
of a heterogeneous group of IBS patients with severe symptoms
is hard to interpret or relate to the symptoms of IBS (Torn-
blom et al., 2002), which are primarily due to colonic motor
dysfunction.
Several other lines of evidence speak against a role of mild
mucosal inﬂammation in motility dysfunction in PI-IBS/NI-IBS
patients.
1. Prednisone treatment in a reasonably large cohort of PI-
IBS patients decreases the lamina propria T lymphocyte
counts and probably other inﬂammatory cells without a con-
current improvement in the symptoms of abdominal pain,
diarrhea, or urgency substantiates the hypothesis that the
physiological/sub-clinical inﬂammation is not the underlying
factor in IBS symptoms (Dunlop et al., 2003b).
2. The increases in T lymphocytes in lamina propria and IELs
in PI-IBS and NI-IBS are not consistent among different
studies – some reporting signiﬁcant increases, while others
reporting no change (Gwee et al., 1999; Spiller et al., 2000;Dun-
lop et al., 2003a; Lee et al., 2008). More importantly, one study
found that the lamina propria T lymphocytes remained signif-
icantly elevated in patient controls (those who have enteritis,
but do not develop PI-IBS) over healthy controls (Dunlop et al.,
2003a). The surface IELs were not different among PI-IBS,
patient controls, and healthy controls. The crypt IELs numbers
were lower in PI-IBS and patient controls vs. healthy con-
trols. The symptoms of IBS had subsided in patient controls
at this time, which questions the role of elevated lymphocytes
in causing them.
3. The intensities of inﬁltration of immunocytes in IBS-D and
IBS-C patients do not differ (Cremon et al., 2009). The same
stimulus could not explain the diametrically opposite effects
on colonic motor function in IBS-D and IBS-C patients.
4. Rectal hypersensitivity, and colon transit are similar in PI-IBS+
and PI-IBS− patients following enteric infection, even though
the PI-IBS+ have elevated mucosal inﬂammatory cell counts
over those who did not develop IBS symptoms (PI-IBS−; Gwee
et al., 1999).
LESSONS LEARNT
1. The inﬂammatory response is a continuum (Figure 1). A basal
level of immune activation is necessary to protect the gut wall
from the hostile environment in the gut lumen – physiolog-
ical inﬂammation. The next is the sub-clinical level, where
the inﬂammation increases signiﬁcantly over the physiological
level; however, it is not enough to impair the function of cells in
its environment (PI-IBS and NI-IBS). The third level is path-
ogenic, which impairs the function of cells in its environment
accompanied with mild structural damage (Microscopic coli-
tis). The fourth is severe pathogenic,which impairs the function
of cells in its environment accompanied with severe structural
damage and/or change in phenotype (IBD).
2. The symptoms of IBS relate to disturbances in the frequency
of GMCs. The monitoring of these contractions is central to
identifying the causative factors of motility dysfunction in IBS.
3. The biopsy tissues are available from IBS patients and
healthy subjects – however, the mild/inconsistent inﬂamma-
tory response detected in mucosal biopsies is unable to predict
smooth muscle/enteric neuronal dysfunction in the muscularis
externa that directly regulate normal and abnormal frequency
of GMCs and hence motility dysfunction in PI-IBS and NI-IBS
patients.
4. Even though the symptoms of IBD and IBS patients are similar,
they do not have the same etiologies, such as inﬂammation.
5. The similarity of the immunological inﬁltrate in PI-IBS andNI-
IBS patients suggests that the prior enteric infection is unlikely
to be the cause of mild mucosal inﬂammation in these patients.
ENTEROCHROMAFFIN (EC) CELL HYPERPLASIA AND
MOTILITY DYSFUNCTION IN PI-IBS
The ﬁndings of EC cell hyperplasia in the mucosa of PI-IBS/NI-
IBS patients are divergent – some found a signiﬁcant, but modest,
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increase (Spiller et al., 2000; Dunlop et al., 2003a) – others did not
(Coates et al., 2004; Park et al., 2006). The hyperplasia of a cell type
does not necessarily mean that it will release more of its contents,
which depends on complex cell signaling andmicroenvironment –
this is one of the reasons that immunohistochemical staining alone
is insufﬁcient to establish a cause and effect relationship. EC cell
hyperplasia, if it is present,does not translate into an increase in the
release of 5-HT in the mucosa of IBS patients (Coates et al., 2004).
Paradoxically, themucosal serotonin decreases in IBS patients even
though the plasma serotonin increases (Dunlop et al., 2005). The
source of increase plasma serotonin is unknown and there is no
evidence that it has a signiﬁcant effect on colonic motility orVHS.
The serotonin transporter (SERT) mRNA expression also does
not change in IBS patients (Camilleri et al., 2007). Recent studies
show that the mucosal release of 5-HT is not required to stimu-
late GMCs in response to distention in the guinea pig and mouse
colons (Keating and Spencer, 2010; Spencer et al., 2011). Overall,
the available evidence weighs heavily against a potential role of EC
cell hyperplasia in causing motility dysfunction or VHS in PI-IBS
or NI-IBS patients.
The release of serotonin from EC cells in response to villus
stimulation by the ingested meal activates the intrinsic sensory
neurons (Bulbring and Crema, 1959), which in turn stimulate the
release of excitatory and inhibitory neurotransmitters from the
myenteric motor neurons via interneurons (Grider and Jin, 1994;
Gershon, 2005). Thereafter, the myenteric neuronal circuits and
smooth muscle excitation–contraction coupling together deter-
mine whether the resulting contractions will be GMCs, RPCs,
or TCs (Sarna, 2006, 2010). As noted earlier, each type of con-
traction has a different effect on motility function. It is too sim-
plistic to assume that an increase or decrease in the availability
of serotonin in the mucosa alters postprandial transit in intact
organisms. This is one of the reasons that partial or full 5-HT4
agonists are marginally effective or effective only in a subset of IBS
patients in improving the global symptoms of IBS (Brandt et al.,
2002).
Additional evidence that speaks against a potential role of EC
cell hyperplasia as a causative factor for motility dysfunction or
VHS in IBS patients is:
1. A double blind, randomized, placebo-controlled clinical trial
with serotonin reuptake inhibitor ﬂuoxetine found no signif-
icant effect on rectal hypersensitivity and the symptoms of
abdominal pain, bloating, ﬂatulence, incomplete evacuation
and urgency in a mixed group of IBS-C, IBS-D and IBS-C/D
patients (Kuiken et al., 2003) – suggesting that none of their
symptomswere due to a decrease in the availability of serotonin
in the mucosa or elsewhere.
2. The mucosal 5-HT, tryptophan hydroxylase1, SERT are all
signiﬁcantly reduced in the mucosal biopsies of ulcerative col-
itis, IBS-D and IBS-C patients (Coates et al., 2004). A similar
decrease inmucosal 5-HT could not explain faster colonic tran-
sit in ulcerative colitis and IBS-D patients and slower transit in
IBS-C patients. Consequently, a small increase in EC cell num-
bers noted by some studies is unlikely to be the cause of IBS
symptoms.
LESSON LEARNT
1. There is little evidence that a decrease or increase in serotonin
release/availability in the mucosa decreases or increases the fre-
quency of GMCs. Note that the GMCs occur only a few times
(2–5) per day, while serotonin release is stimulated constantly
due to continuous presence of fecal material in the colon.
MAST CELL HYPERPLASIA AND VISCERAL
HYPERSENSITIVITY IN PI-IBS/NI-IBS
FACTORS CONTRIBUTING TO ABDOMINAL PAIN
The sensation of pain in response to colorectal distension (CRD)
by a balloon is a standard test to evaluate hypersensitivity of the
afferent neurons or impaired processing of supraspinal signals
that might contribute to the symptom of intermittent abdomi-
nal pain/cramping in IBS patients. The sensation in this test lasts
for the duration of balloon distension, which shows that hyper-
sensitivity, by itself, does not cause the sensation of intermittent
cramping – a mechanical event, such as colon wall distension, is
required. The patients feel similar cramping episodes in their rou-
tine lives without balloon distensions in their colons. Obviously, in
routine life, the colon contractions, instead of balloon distension,
distort afferent nerve endings to generate afferent signals.
As discussed earlier in this review, the colon generates three
distinct types of contractions, RPCs, GMCs, and TCs. The GMCs
have the largest amplitude and they can propagate uninterrupt-
edly over long distances in the colon to produce mass movements.
They also generate descending inhibition of ongoing RPCs and
tone, especially of the anal internal anal sphincter to relax it in
preparation for defecation (Bassotti et al., 1999). The intensity
of afferent signals generated by mechanical stimuli in the gut is
proportional to the amplitude of contraction or distension, which
makes GMCs the prime candidates to generate nociceptive sig-
nals. Note that the RPCs are present somewhere in the colon all
the time. However, their amplitudes are invariably sub nocicep-
tive threshold – if that were not the case, we will feel abdominal
pain all the time. The complimentary roles of VHS and GMCs
in producing the symptom of abdominal cramping are discussed
in depth elsewhere (Sarna, 2010). The following provides a brief
summary as background for discussion of the role of mast cell
hyperplasia/activation in generating the symptom of intermittent
abdominal cramping in IBS patients.
1. In health, the maximum amplitude of colonic GMCs is sub
nociceptive threshold. Therefore, their infrequent presence in
the colon is not painful (Figure 3A).
2. The amplitudes of GMCs nearly double to above nociceptive
threshold in the colons of IBS-D patients with moderate to
severe diarrhea (Chey et al., 2001). In this condition, VHS is
not required for the sensation of abdominal cramping, when
a GMC occurs in the colon (Figure 3B). However, concurrent
VHSwouldworsen the sensation. It is noteworthy that, on aver-
age,only about 50%of IBSpatients demonstrateVHS,although
more that 90% of them complain of abdominal cramping
(Prior et al., 1990; Lembo et al., 1994; Kuiken et al., 2005;
Posserud et al., 2007; Camilleri et al., 2008).
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FIGURE 3 | Cartoon showing the conditions under which GMCs generate
afferent signals that exceed the nociceptive threshold. (A) In normal state,
the afferent signal generated by a GMC is above the pseudoaffective
threshold, but below the nociceptive threshold. The descending inhibition
prevents the receiving segment from generating tone and hence afferent
signals. No sensation of pain develops. (B) Due to enteric neuromuscular
dysfunction, the amplitude of GMCs increases so that the afferent signals
generated by them exceed the nociceptive threshold and painful sensation
results. (C) Visceral hypersensitivity of the afferent neurons or impaired
processing of signals in the CNS effectively lowers the nociceptive threshold
so that the afferent signal generated by a GMC of normal amplitude exceeds
the threshold for perception of pain. (D) Due to impairment of descending
inhibition, the receiving segment generates tone and sends afferent signals.
These signals add to those generated by the GMC.The combined signal
exceeds the nociceptive threshold to induce the sensation of pain
(Reproduced with permission from Sarna, 2010).
3. The second scenario is that a signiﬁcant increase in VHS low-
ers the nociceptive threshold to a level such that the affer-
ent signals generated by normal amplitude GMCs (about
110mm Hg) generate nociceptive signals to cause the sensation
of abdominal cramping (Figure 3C).
4. Of the three types of colonic contractions, only the GMCs con-
tract colon segments strongly enough to produce descending
inhibition of RPCs and relaxation of internal anal sphincter as
the GMC approaches it (Sarna, 2010). The purpose of descend-
ing inhibition is to prevent the distal receiving segment from
contracting, and at the same time allow it to relax to accommo-
date the large contents of mass movement without generating
afferent signals. However, if the descending inhibition were
impaired, the receiving segmentwould distendunder tension to
generate afferent signals of its own, which add up to those pro-
duced by the GMC itself (Figure 3D). Similarly, if the internal
sphincter does not relax due to impaired descending inhibi-
tion, the approaching GMS will push fecal contents against a
closed anal sphincter to distend the intervening segment and
send afferent signals to add to those being generated by the
GMC. The combined afferent signals might exceed the noci-
ceptive threshold to induce abdominal cramping (Figure 3D).
In this case, also, VHS is not required, but, if present, it would
worsen the sensation.
MAST CELL HYPERPLASIA IN PI-IBS
Some studies found mast cell hyperplasia and an increase in the
release of their products (histamine, tryptase) in themucosal biop-
sies from the rectum of PI-IBS and NI-IBS patients (O’Sullivan
et al., 2000; Park et al., 2003; Barbara et al., 2004, 2007; Cenac
et al., 2007; Cremon et al., 2009). Others found a positive cor-
relation between the mast cell numbers in close proximity (less
than 5μm) to nerve endings and IBS symptoms. Based on these
ﬁndings, they proposed that the products of the mast cells in close
proximity to enteric nerve endings induce VHS (Barbara et al.,
2004, 2007). There are several limitations of this hypothesis. (1)
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These studies did not identify that the mucosal nerves closely
associated with mast cells were indeed extrinsic afferent nerves.
Instead, they prepared supernatants from the mucosal biopsies
and added them to the colons of mice to show that they acti-
vate afferent neurons. However, they did not demonstrate that
the concentrations of mast cell products in the supernatants were
similar to those in the intact mucosa. The method of prepa-
ration of supernatants could easily concentrate the mast cell
products enough to show a pharmacological effect in the mouse
colon. The mast cell products are stable in supernatants – they
degrade rapidly in situ in the intact mucosa. In addition, the
spontaneous release of mast cell mediators is an inappropriate
biomarker for the role of mast cells in evaluating their role in
disease (Klooker et al., 2010). (2) Ulcerative colitis patients show
signiﬁcant mast cell hyperplasia (Middel et al., 2001) and yet most
studies show that these patients do not developVHS (Chang et al.,
2000). (3) Other studies found no signiﬁcant increase in rec-
tosigmoid mast cells or their products in the mucosal biopsies
of PI-IBS and/or NI-IBS patients (Spiller et al., 2000; Chad-
wick et al., 2002; Dunlop et al., 2003c; Wang et al., 2004; Cenac
et al., 2007; Klooker et al., 2010). Mast cell hyperplasia occurs in
diarrhea-predominant PI-IBS patients, but not in constipation-
predominant or alternating diarrhea/constipation patients – yet
patients in all three types of IBS feel abdominal cramping (Lee
et al., 2008). (4) Statistical correlation between two biological vari-
ables does not establish a cause and effect relationship between
them. A third independent variable might regulate teach of them
independently. Morphological and immunohistochemical obser-
vations, by themselves, are insufﬁcient to establish cause and
effect relationships.Close associationdoes not automatically prove
causation.
Several additional lines of evidence speak against a role of mast
cell hyperplasia close to mucosal nerve endings as the underlying
cause of the symptom of abdominal cramping in IBS patients.
1. Clinical trialswith ketotifen,amast cell stabilizer (Klooker et al.,
2010), and mesalazine (Corinaldesi et al., 2009) showed no
effect on abdominal pain, bloating, or bowel habits. Mesalazine
reduced mucosal immune cells, including mast cells. Ketotifen
increased the threshold for discomfort and improved IBS symp-
toms without a change in mucosal mast cell numbers or release
of their products, histamine, and tryptase, discounting a role of
immune cells, including mast cells in generating the symptoms
of IBS. This study found that the mucosal mast cell numbers
and spontaneous release of tryptase were lower in IBS patients
than in healthy volunteers.
2. A well-designed and rigorously executed study found that
patients with low-grade chronic inﬂammation in inactive/mild
ulcerative colitis had a higher threshold to recto-sigmoidal dis-
tension than healthy controls (Chang et al., 2000). By contrast,
IBS patients with similar chronic inﬂammatory conditions in
the mucosa have lower sensory thresholds to recto-sigmoidal
distension. The IBS, ulcerative colitis patients, and healthy
controls did not differ in psychological symptom scores and
rectal compliance. Chronic mild inﬂammation of the esopha-
gus and stomach also do not associate with visceral mechanical
hyperalgesia (Fass et al., 1998; Mertz et al., 1998).
3. Accumulating evidence from human (Lembo et al., 1997) and
animal (Lynn and Blackshaw, 1999; Brierley et al., 2004) stud-
ies show that the splanchnic nerves with mechanoreceptors
in the muscularis externa/serosa mediate afferent signaling in
response to rapid balloon distensions – GMCs cause rapid
gut wall compressions. In vitro, the mucosal afferents do not
respond to circumferential stretch – but, they respond to mild
mucosal stoking by von Frey hairs that simulates the ﬂow of
digesta (Lynn andBlackshaw,1999;Brierley et al., 2004). In vivo,
the mucosal afferents respond to slow distensions that mimic
slow lumen ﬁlling, but not to rapid balloon distension (Lembo
et al., 1997). The desensitization of mucosal mechanoreceptors
by lidocane does not block pain perception to rapid balloon
distension in IBS patients – it blocks the sensation to slow
distension (Lembo et al., 1994). The inﬂammation in the lam-
ina propria/epithelium is not in the microenvironment of the
mechanoreceptors of splanchnic afferents in the muscularis
externa/serosa to modulate their function.
Taken together, the above ﬁndings show that chronic mild inﬂam-
mation of the mucosa in IBS patients does not relate to VHS. This
review does not discuss the roles of mast cells in experimental
models of IBD or IBS.
LESSONS LEARNT
1. Visceral hypersensitivity and generation of GMCs are both
critical players in generating the symptom of intermittent
abdominal cramping in IBS patients. VHS, by itself, does not
produce this sensation – a mechanical event, such as, a strong
colonic contraction or colon wall distension or both are essen-
tial. The sensation of cramping lasts as long as a GMC is present
anywhere in the colon (∼1–2min).
2. Spatial association, by itself, does not establish cause and effect
relationship.
EPITHELIAL PERMEABILITY AND POST-INFECTIOUS IBS
The interphase between the gut and the lumen is a sophisticated
barrier that keeps the luminal microbes, incompletely digested
proteins, and pathogens at bay, while allowing the nutrients to
pass through. However, this barrier is vulnerable to adverse stim-
uli from the lumen as well as from biological/pathological events
within the gutwall.An increase in luminal pathogenic load impairs
the barrier. The subsequent access of the microbes or their prod-
ucts to the sterile structures in the gut wall initiates an immune
response, whose intensity, and proﬁle depend upon the volume
and phenotypes of pathogens. To make things worse, the inﬂam-
matory mediators might further erode the barrier (Chavez et al.,
1999), setting up a vicious cycle until the anti-inﬂammatorymech-
anisms achieve a dynamic equilibrium. Biological events, such as
psychological stress, operate fromwithin the gutwall. These events
activate resident immunocytes, such as mast cells, whose products
impair the barrier to cause inﬂux of luminal pathogens, which
might enhance barrier dysfunction until a dynamic equilibrium
is achieved. Fortunately, the adverse effects of mucosal inﬂamma-
tory response are sub-clinical within a wide range of this dynamic
equilibrium.
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In context of the above, diarrhea-predominant IBS patients
show increase in colonic permeability (Spiller et al., 2000; Dunlop
et al., 2006) – constipation-predominant patients do not (Dunlop
et al., 2006). Other studies found no differences in small intestinal
permeability between patients, who developed PI-IBS and those
whodid not, 2 years following acute gastroenteritis (Marshall et al.,
2004) and in NI-IBS patients vs. healthy subjects (Dainese et al.,
1999; Tibble et al., 2002). A subset of diarrhea-predominant PI-
IBS patients showed a small, but statistically signiﬁcant, increase in
small intestinal permeability above the conventional cut off limit
of 0.03 in lactulose/mannitol ratio (Spiller et al., 2000). In another
group of diarrhea-predominant IBS patients, the majority (61%)
had small intestinal permeability within the normal range – yet
they presented with symptoms similar to those with permeability
above the normal range (Zhou et al., 2009). The patients with
increase in small intestinal permeability had higher functional
bowel disorder severity index. It is likely that chronic stress caused
increase in small intestinal permeability, rather that small intestinal
permeability causing VHS to CRD. Note that the small intestinal
permeability in collagenous colitis patients with secretory diarrhea
also does not differ from that in controls (Wildt et al., 2006). This
is hardly surprising because collagen colitis should correlate with
changes in colonic permeability, rather than to changes in small
intestinal permeability. Small intestinal or colonic permeability
does not correlate with colonic transit or bowel frequency/week
(Dunlop et al., 2006). It is hard to assign a signiﬁcance to increase
in small intestinal permeability to the motility dysfunction or
abdominal cramping in IBS patients, which relate mostly to the
abnormalities in the colon. Overall, small intestinal permeability
is an unlikely biomarker of IBS.
Intestinal inﬂammation and a systemic response to antigens
can develop in the absence of disruption to intestinal permeability
(Sydora et al., 2006a,b).
LESSON LEARNT
1. Measurements of small intestinal permeability cannot predict
similar changes in the colon and they do not relate to the
primary symptoms of IBS – diarrhea/constipation and VHS.
2. The GMCs are ultra-strong contractions and their frequency
increases in IBS-D patients. Frequent strong compressions of
the colon wall by GMCs could damage the epithelium to
increase its permeability. The frequency of GMCs decreases in
IBS-C patients – they show no change in colonic permeability.
Note that the concurrent increase in the frequency of GMCs
and mucosal friability in ulcerative colitis patients results in
bleeding and mucus discharge (see Sarna, 2010 for details).
Bleeding or mucus discharge does not occur in IBS-D patients
because of intact mucosal structure.
GENETICS, EPIGENETICS, AND POST-INFECTIOUS IBS
GENETIC AND EPIGENETIC BASIS OF DISEASE
Organs develop from a single zygote under the guidance of
genomic and epigenetic information inherited from both parents.
The genome has the code (DNA sequences) for the correct syn-
thesis of all proteins required by an organism – the epigenome
has the means to set the transcription rates of genes encoding
these proteins. The expression of a unique group of proteins at the
correct levels imparts phenotype to each cell type in an organ. Epi-
genetic mechanisms regulate gene expression without a change in
DNA sequence. DNA replication mechanisms during meiotic and
mitotic cell divisions maintain its integrity except under extreme
environmental conditions, such as toxins and ionizing radiation.
By contrast, the epigenetic mechanisms are highly sensitive to
cellular environment throughout life, especially during fetal and
neonatal stages of development.
Amutation in gene sequence, inherited from the parents, causes
aMendelian or simple disease – e.g., sickle cell anemia,hemophilia,
and cystic ﬁbrosis, if it is at a locus in the coding region critical
for the synthesis of correct amino acid sequence of the protein,
or it is in 5′ ﬂanking promoter region that is essential to initiate
transcription. These diseases have early onset in life and worsen
progressively (Childs, 1995). By contrast, complex diseases arise
from a combination of changes in one or more cell phenotypes
that accumulate over a period. The search for gene mutations
underlying complex diseases –diabetes, most cancers, and asthma
has largely been unsuccessful. Complex diseases exhibit an inher-
itable component, but do not follow Mendel’s laws. For example,
discordance of monozygotic twins reaches 30–50% in diabetes,
70% in multiple sclerosis and rheumatoid arthritis, and 80% in
breast cancer (King et al., 1992). Differential exposures to environ-
ments usually explain these discordances. Complex diseases tend
to appear later in life, show gender differences, parent-of-origin
effects, remissions, and relapses and more than one peak (Howard
et al., 2000). Functional Bowel Disorders fall into the category of
complex diseases. These disorders are likely to relate to epigenetic
dysregulation.
POLYMORPHISMS AND PI-IBS/NI-IBS
The DNA sequence of approximately 3.2 billion bases is roughly
99.9% similar between any two individuals – the remaining 0.1%
(approx. 7 million bases) makes individuals unique. These varia-
tions in sequences among individuals, called mutations, polymor-
phism, insertions, and deletions are inheritable. Variations may
be in one base (single nucleotide polymorphism, SNP) or in a
sequence of bases of variable length. A variation in one base in
less than 1% (arbitrary number) of the population is a mutation –
greater than this number is polymorphism.Avastmajority of these
variations have no effects on the attributes of humans because only
about 3%of theDNA sequence contains the coding and regulatory
(promoters) sequences – the rest of the DNA sequence is mostly
non-coding and non-regulatory – however, it might contain some
enhancer and repressor elements that can inﬂuence transcription
of distant genes. In essence, these variations have the potential to
affect the attributes of individuals or make them susceptible to
diseases, if they are in the coding or the regulatory region. In the
coding region, they would have a detrimental effect if the altered
amino acid changes the protein coded by the gene. In the regula-
tory region, these variations could reset the rate of transcription of
the gene, if they arewithin the recognition sequences (or close to it)
of the transcription factors that regulate the constitutive or evoked
expression of the affected gene. Even though most polymorphisms
are harmless, they might alter the response of therapeutic agents
or environmental toxins because they might activate transcription
factors not generally utilized in health.
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A recent thorough and rigorous study identiﬁed SNPs in the
coding and regulatory regions of genes regulating IL-6,CDH1, and
Toll-like receptor-9 (TLR-9) inPI-IBSpatients (Villani et al., 2010).
The investigators chose these candidate genes on the assumption
that a mild immune cell inﬁltration and increase in epithelial per-
meability are the causes of altered motility and visceral sensory
functions in IBS patients. However, as per discussions in previ-
ous sections, there is little evidence to support this assumption. In
addition, the frequencies of alleles in PI-IBS patients were of the
same order of magnitude as in controls, which beg the question
why did they not cause symptoms in controls. It is noteworthy,
that a change in phenotype due to polymorphism is permanent –
the IBS symptoms are relapsing and recurring. Polymorphism
studies in NI-IBS patients have focused on genes encoding the
SERT, TNFα, and IL-10 – all of which lack compelling evidence to
show that they play a role in motility dysfunction in IBS patients
(see earlier sections). These studies yielded conﬂicting or nega-
tive ﬁndings regarding polymorphisms in these genes (Pata et al.,
2002; Kim et al., 2004; Lee et al., 2004; Yeo et al., 2004; van der
Veek et al., 2005) – meta analysis found no correlation between
polymorphism in SERT gene and IBS symptoms (Van Kerkhoven
et al., 2007). Taken together, there is little compelling evidence for
a genetic background for IBS. Several reviews have discussed addi-
tional serious limitations of polymorphism data in explaining IBS
(Park and Camilleri, 2005; Saito and Talley, 2008; Vermeire et al.,
2010).
The studies on polymorphisms are descriptive and inconclu-
sive unless followed up by further studies to establish that the SNP
affects the binding of one ormore transcription factors to the regu-
latory region to affect the transcription rate of the gene, or to show
that the SNP in the coding region affects the synthesis of the pro-
tein encoded by the gene. A more effective approach is to identify
ﬁrst a protein that alters smooth muscle, myenteric neuronal, or
afferent neuronal function and then investigate whether its gene
has a mutation in its coding or regulatory region that explains
altered protein expression in cohorts of IBS patients. Note that
aberrant protein synthesis is not a feature of complex diseases –
biological effects of polymorphisms do not fade away and recur.
While it is hard to envisage a role of polymorphisms in a complex
disease, such as IBS, polymorphisms might explain varying inten-
sities of enteritis in subjects exposed to the same infectious agent.
Polymorphisms might also explain differential sensitivities of IBS
patients to therapeutic agents (Camilleri et al., 2002).
EPIGENETIC DYSREGULATION AND PI-IBS/NI-IBS
Early life psychological trauma/stress is a known risk factor for
the development of IBS in adulthood (Chitkara et al., 2008). Gut
inﬂammation is another major early life stressful condition (Low-
man et al., 1987; Chitkara et al., 2008). The annual episodes of
diarrhea in U.S. children less than 5-year-old ranges from 20 to 35
million (Pont et al., 2009). These diarrheal episodes lead to about
22,000 hospitalizations per year, indicating the severity of enteri-
tis. The epigenetic programming of genes begins at the start of
fetal development and continues in early life. During these peri-
ods, epigenetic mechanisms program the genes for normal health
in adulthood. However, in the face of stressful conditions, they
reprogram the genes for immediate survival. Unfortunately, the
reprogramming of genes might persist in adulthood, resulting in
aberrant rates of gene expressions to cause organ dysfunction.
Fourmechanisms constitute epigenetic regulation of gene tran-
scription – transcription factors, DNA methylation, histone codes
(acetylation, methylation, phosphorylation, ubiquitination, and
sumoylation of lysine residues on the N-terminal tails of histone
proteins), and micro RNAs (Bhaumik et al., 2007). The post-
translationalmodiﬁcationof histoneproteins alters the interaction
between DNA and chromatin, which regulates the access of tran-
scription factors to their recognition sequences to initiate gene
transcription. Epigenetic programming/reprogramming is gene,
stimulus and cell-type speciﬁc. Unlike mutations/polymorphisms,
the epigenetic programming is dynamic – it responds to environ-
mental stimuli throughout life, especially during vulnerable stages
of fetal and neonatal developments.
ANIMAL MODELS OF IBS
The symptoms of IBS arise from dysfunctions in smooth muscle
cells,myenteric neurons, afferent neurons, and possibly the central
nervous system. The access to these tissues for scientiﬁc investi-
gations in humans is severely limited. Biopsy tissues are available,
but experiences with PI/IBS and NI-IBS patients show that they
might have little use in predicting dysfunctions of the above cell
types associated directly with the symptoms of IBS. The alternate
approach is to develop animal models of sub-types of IBS with the
full understanding that animal models do not mimic full human
diseases. However, these models can provide valuable information
on speciﬁc aspects of human disease. Testing of these ﬁndings
in human patients for diagnostic and therapeutic purposes will
advance the ﬁeld.
Numerous animal models support the hypothesis that neona-
tal inﬂammatory or psychological insults result in two cardinal
IBS-like dysfunctions in adulthood – altered motility function
and VHS. A neonatal inﬂammatory insult (trinitrobenzene sul-
fonic acid, 130mg/kg) enhances smooth muscle reactivity to ACh,
accelerates colon transit, increases fecal pellet output per 24-h
and increases fecal water content in adulthood (Choudhury et al.,
2009). These effects result from alterations in the expressions of
key genes that regulate smoothmuscle excitation–contraction cou-
pling and sensitivity of primary afferent neurons to cause IBS-like
symptoms (Choudhury et al., 2009).A similar inﬂammatory insult
in adult rats does not cause diarrhea-like conditions, 6–8weeks
later. Inﬂammatory insult with mustard oil, colon irritation, or
maternal deprivation in neonates results in VHS to CRD in adult-
hood (Al-Chaer et al., 2000; Coutinho et al., 2002; Barreau et al.,
2004).
It is noteworthy that the inﬂammatory/psychological stress in
neonates has to be intense and/or chronic to cause dysfunctions
in adulthood (Al-Chaer et al., 2000; Coutinho et al., 2002; Bar-
reau et al., 2004; Choudhury et al., 2009). For example, a smaller
dose of TNBS or duration of maternal deprivation in neonates
does not cause colonic motor or sensory dysfunction in adult-
hood (Choudhury et al., 2009). The question arises why these
stressors induce persistent VHS and colonic motor dysfunction in
neonates, but not in adults. The answer is epigenetic dysregulation
during the vulnerable stages of fetal and neonatal developments.
As the organisms develop from a single zygote, the DNA replicates
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at each asymmetric or symmetric cell division. In addition, at each
cell division, the epigenetic mechanisms program the expression
of each gene to impart cell phenotype. Inherited epigenetic infor-
mation programs genes for normal health in adulthood. However,
in the face of intense or chronic psychological/chemical stress,
the epigenetic mechanisms reprogram the genes to protect vital
organs in neonates, such as the heart, to ensure survival. This
aberrant epigenetic regulation also affects the programming of
genes in other organs that are vulnerable at the time of the insult.
Unfortunately, this reprogramming persists in adulthood to cause
organ dysfunctions, resulting in complex diseases (Nuyt, 2008).
Neonatal inﬂammatory insult increases the acetylation and
trimethylation of lysine residue nine on histone H3 to enhance the
association of RNApolymerase II with the core promoter region of
the Cacna1c. This gene encodes the pore-forming α1C subunit of
Cav1.2b (L-type) calcium channels in smooth muscle cells (Saada
et al., 2003). This epigenetic modulation increases the transcrip-
tion of this gene (Li and Sarna, 2011). The resulting increase of
calcium inﬂux through these channels enhances the amplitude of
colonic contractions, accelerates colonic transit, and fecal output
(Shi et al., 2007; Choudhury et al., 2009). It is noteworthy that a
similar insult in adulthood does not produce these effects empha-
sizing the vulnerability of genes during development. However, an
inﬂammatory insult in adult rats causes DNA damage that recov-
ers partially after the insult – the persistent damage associates
with suppression of smooth muscle reactivity to ACh (Choi et al.,
2011a).
Clinical studies show a strong link between early life infec-
tion and development of IBS and dyspepsia in adulthood (Saps
et al., 2008). Eighty-seven percentage of children in the age
range of 3–19 years developed IBS following acute gastroenteri-
tis [Salmonella (54%), Campylobacter (32%), and Shigella (14%)]
and 24% develop dyspepsia (Saps et al., 2008). It is noteworthy
that in animal model, neonatal inﬂammatory insult concurrently
causes gastric hypersensitivity to gastric distension (Winston and
Sarna, 2011) and moderate delay in gastric emptying (Choi et al.,
2011b) – the two cardinal symptoms of functional dyspepsia.
The concurrent induction of IBS-like symptoms in the colon
and functional dyspepsia-like symptoms in the stomach following
neonatal inﬂammatory insult highlights overlap seen in subsets of
patients with IBS and functional dyspepsia (Geeraerts and Tack,
2008).
LESSONS LEARNT
1. Epigenetic regulation modiﬁes the expression of selective genes
in cells following changes in their microenvironment.
2. If the changes in microenvironment occur during the vulner-
able stages of fetal and neonatal development, the changes in
expressions of selective genes may persist into adulthood to
cause complex diseases, such as IBS.
3. The relapsing/recurring changes in symptoms of IBS do not
make them candidates for genetic mutations/polymorphisms.
CONCLUSION
Mounting evidence suggests that post-translational modiﬁcations
of histone proteins by environmental stimuli at various stages
of development and maturity are major factors in a variety of
diseases, including cancer, inﬂammatory disorders, and autoim-
mune diseases (Egger et al., 2004). Based on these advances, novel
histone deacetylase inhibitors are under development to treating
complex diseases – some types of cancers and diabetes mellitus
(Butler et al., 2002; Kumagai et al., 2007; Lawless et al., 2009; Chris-
tensen et al., 2011). The investigations of epigenetic dysregulation
in functional bowel disorders are beginning to emerge. Overall, a
paradigm shift from technology-driven approach (ready availabil-
ity of mucosal biopsies and blood samples, immunoﬂuorescence
and assay methodologies) to hypothesis-driven approach (inves-
tigations of smooth muscle cells, enteric neurons, visceral afferent
neurons, and CNS) will advance our understanding of functional
bowel disorders and help in development of novel therapies.
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